Management of chronic viral hepatitis in the hematological patient

References

• WHO. Global hepatitis report. Geneva. 2017 [cited 23 November 2017]. Available from: http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1.
   Google Scholar
• Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7(1):31–40.
   PubMed Web of Science ®Google Scholar
• Kamar N, Dalton HR, Abravanel F, et al. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27(1):116–138.
   PubMed Web of Science ®Google Scholar
• Versluis J, Pas SD, Agteresch HJ, et al. Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood. 2013;122(6):1079–1086.
   PubMed Web of Science ®Google Scholar
• Farci P. Delta hepatitis: an update. J Hepatol. 2003;39 Suppl 1:S212–S219. PubMed PMID: 14708706; eng
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Yokokawa Y, Morino K, et al. Chronic hepatitis E: a review of the literature. J Viral Hepat. 2014 Feb;21(2):78–89. PubMed PMID: 24383921; eng.
   PubMed Web of Science ®Google Scholar
• Dalia S, Chavez J, Castillo JJ, et al. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013 Sep;37(9):1107–1115. PubMed PMID: 23809055; eng.
   PubMed Web of Science ®Google Scholar
• Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Prev Biomark. 2006;15(11):2078–2085.
   PubMed Web of Science ®Google Scholar
• Salah-Eldin MA, Ebrahim MA, El-Sadda W. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy. Ann Hematol. 2014 Nov;93(11):1903–1911. DOI:10.1007/s00277-014-2138-5. PubMed PMID: 24951125; eng.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008 Oct;49(4):652–657. PubMed PMID: 18715666; eng.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology (Baltimore, MD). 2007;45(2):507–539.
   PubMed Web of Science ®Google Scholar
• Dunn C, Brunetto M, Reynolds G, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med. 2007 Mar 19;204(3):667–680. PubMed PMID: 17353365; PubMed Central PMCID: PMC2137916. eng.
   PubMed Web of Science ®Google Scholar
• Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells [Review]. Nat Med. 2013;19(7):859–868.
   PubMed Web of Science ®Google Scholar
• Chang M-L, Liaw Y-F. Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management. J Hepatol. 2014;61(6):1407–1417.
   PubMed Web of Science ®Google Scholar
• EASL. Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370–398. PubMed PMID: 28427875; eng. DOI:10.1016/j.jhep.2017.03.021.
   PubMed Web of Science ®Google Scholar
• Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001 Mar;120(4):1009–1022. PubMed PMID: 11231956; eng.
   PubMed Web of Science ®Google Scholar
• Mallet V, Van Bommel F, Doerig C, et al. Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis. 2016 May;16(5):606–617. PubMed PMID: 27599653; eng.
   PubMed Web of Science ®Google Scholar
• Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012 Jan 24;9(3):156–166. PubMed PMID: 22271089; eng. DOI:10.1038/nrclinonc.2012.1.
   PubMed Web of Science ®Google Scholar
• Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):209–219. DOI:10.1038/nrgastro.2013.216. PubMed PMID: 24247262; PubMed Central PMCID: PMCPmc4170710. eng.
   PubMed Web of Science ®Google Scholar
• Lenci I, Marcuccilli F, Tisone G, et al. Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis. Dig Liver Dis: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2010 Aug;42(8):578–584. PubMed PMID: 20097143; eng.
   Google Scholar
• Sarmati L, Andreoni M, Antonelli G, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2017 Jun 29. PubMed PMID: 28668466; eng. DOI:10.1016/j.cmi.2017.06.023.
   Google Scholar
• Awerkiew S, Daumer M, Reiser M, et al. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clinic Virol: the official publication of the Pan American Society for Clinical Virology. 2007 Jan;38(1):83–86. PubMed PMID: 17134939; eng.
   PubMed Web of Science ®Google Scholar
• Gärtner BC, Jung W, Welsch C, et al. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. J Clin Virol. 2007;38(2):146–148.
   PubMed Web of Science ®Google Scholar
• Marzano A, Bruno R, Fagiuoli S, et al. AISF-Gestione clinica della epatite b negli immunocompromessi: aggiornamento italiano 2017. 2017 [cited 23 November 2017]. Available from: http://www.webaisf.org/media/37755/gestione_clinica_della_epatite_b_negli_immunocompromessi.2017.pdf
   Google Scholar
• Benwell N, Boan P, Raby E, et al. False positive hepatitis B virus core and surface antibodies due to intravenous immunoglobulin. Intern Med J. 2017 Jan;47(1):119–120. PubMed PMID: 28076916; eng.
   PubMed Web of Science ®Google Scholar
• Arnold DM, Crowther MA, Meyer RM, et al. Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion. 2010;50(12):2577–2581.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Cho Y, Lee DH, et al. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014;58(3):1730–1737.
   PubMed Web of Science ®Google Scholar
• Baran B, Soyer OM, Ormeci AC, et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013;57(4):1790–1796.
   PubMed Web of Science ®Google Scholar
• European, Medicines, Agency. Baraclude - drug monograph [cited 23 November 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000623/WC500051984.pdf.
   Google Scholar
• European, Medicines, Agency. Tenofovir disoproxil fumarate- drug monograph [cited 23 November 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000419/WC500051737.pdf.
   Google Scholar
• European, Medicines, Agency. Tenofovir alafenamide- Drug monograph [cited 23 November 2017]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004169/WC500223213.pdf.
   Google Scholar
• Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016;125:63–70.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: survey in Japan, 1987‐1991. Cancer. 1996;78(10):2210–2215.
   PubMed Web of Science ®Google Scholar
• Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991 Jan;100(1):182–188. PubMed PMID: 1983820; eng
   PubMed Web of Science ®Google Scholar
• Lau GK, Leung Y-H, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99(7):2324–2330.
   PubMed Web of Science ®Google Scholar
• Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014 Nov 20;32(33):3736–3743. PubMed PMID: 25287829; eng.
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Bruno B, Alessandrino E, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant. 2003;31(4):295–300.
   PubMed Web of Science ®Google Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013 Aug 01;31(22):2765–2772. PubMed PMID: 23775967; eng.
   PubMed Web of Science ®Google Scholar
• Nakaya A, Fujita S, Satake A, et al. Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA? Leuk Res. 2016 Nov;50:46–49. PubMed PMID: 27665181; eng.
   PubMed Web of Science ®Google Scholar
• Chen FW, Coyle L, Jones BE, et al. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Intl: official journal of the International Association for the Study of the Liver. 2013 Sep;33(8):1203–1210. PubMed PMID: 23522150; eng.
   PubMed Web of Science ®Google Scholar
• Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA: J Am Med Assoc. 2014 Dec 17;312(23):2521–2530. PubMed PMID: 25514302; eng.
   PubMed Web of Science ®Google Scholar
• Chen W-C, Cheng J-S, Chiang P-H, et al. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy. PloS One. 2015;10(6):e0131545.
   PubMed Web of Science ®Google Scholar
• Gentile G, Andreoni M, Antonelli G, et al. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect. 2017;23(12):916–923.
   PubMed Web of Science ®Google Scholar
• Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology (Baltimore, Md). 2017 May;65(5):1451–1461. PubMed PMID: 28027590; eng.
   PubMed Web of Science ®Google Scholar
• Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clinic Infect Diseases: an official publication of the Infectious Diseases Society of America. 2015 Sep 01;61(5):719–729. PubMed PMID: 25935551; eng.
   PubMed Web of Science ®Google Scholar
• Mozessohn L, Chan KKW, Feld JJ, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. J Viral Hepat. 2015;22(10):842–849.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215–219.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Nicolini L, Signori A, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clin Microbiol Infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2014 Oct;20(10):O694–O701. PubMed PMID: 24575948; eng.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009 Feb 01;27(4):605–611. PubMed PMID: 19075267; eng.
   PubMed Web of Science ®Google Scholar
• Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (Baltimore, MD). 2014 Jun;59(6):2092–2100. PubMed PMID: 24002804; eng.
   PubMed Web of Science ®Google Scholar
• Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol: official journal of the European Society for Medical Oncology. 2009 Dec;20(12):2013–2017. PubMed PMID: 19561036; eng.
   PubMed Web of Science ®Google Scholar
• Law MF, Ho R, Cheung CK, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. World J Gastroenterol: WJG. 2016 Jul 28;22(28):6484–6500. PubMed PMID: 27605883; PubMed Central PMCID: PMC4968128. eng.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology (Baltimore, MD). 2009 Sep;50(3):661–662. DOI:10.1002/hep.23190. PubMed PMID: 19714720; eng.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012 Jun;6(3):531–561. PubMed PMID: 26201469; eng.
   PubMed Web of Science ®Google Scholar
• Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American Society of Clinical Oncology provisional clinical opinion update. J Clin Oncol. 2015;33(19):2212–2220. PubMed PMID: 25964247. DOI:10.1200/jco.2015.61.3745.
   PubMed Web of Science ®Google Scholar
• Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):221–244 e3. DOI:10.1053/j.gastro.2014.10.038. PubMed PMID: 25447852; eng.
   PubMed Web of Science ®Google Scholar
• Buti M, Manzano ML, Morillas RM, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study. PloS One. 2017;12(9):e0184550. PubMed PMID: 28898281; PubMed Central PMCID: PMC5595327. eng.
   PubMed Web of Science ®Google Scholar
• Castelli R, Ferraris L, Pantaleo G, et al. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy. Dig Liver Dis. 2016;48(11):1394–1397.
   PubMedGoogle Scholar
• Grossi G, Loglio A, Viganò M, et al. Universal prophylaxis with lamivudine prevents hepatitis B reactivation in HBsAg-negative/anti-HBC positive patients undergoing rituximab-based chemotherapy for non-Hodgkin b cell lymphoma – final results. Abstract 1798. Hepatology (Baltimore, Md). 2016;64(1):888A.
   Google Scholar
• Nakamoto S, Kanda T, Nakaseko C, et al. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment. Int J Mol Sci. 2014 Nov 21;15(11):21455–21467. PubMed PMID: 25421241; PubMed Central PMCID: PMC4264235. eng.
   PubMed Web of Science ®Google Scholar
• Evens AM, Jovanovic BD, Su YC, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol: official journal of the European Society for Medical Oncology. 2011 May;22(5):1170–1180. PubMed PMID: 21115603; PubMed Central PMCID: PMC3082161. eng.
   PubMed Web of Science ®Google Scholar
• Marrone A, Capoluongo N, D’Amore C, et al. Eighteen‐month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. J Viral Hepat. 2017;25(2):198–204.
   PubMed Web of Science ®Google Scholar
• Hui C-K, Sun J, Au W-Y, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol. 2005;42(6):813–819.
   PubMed Web of Science ®Google Scholar
• Hui C, Lie A, Au W, et al. Effectiveness of prophylactic Anti‐HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant. 2005;5(6):1437–1445.
   PubMed Web of Science ®Google Scholar
• Locasciulli A, Alberti A, Bandini G, et al. Allogeneic bone marrow transplantation from HBsAg+ donors: a multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood. 1995;86(8):3236–3240.
   PubMed Web of Science ®Google Scholar
• Lau GK, Lie AK, Kwong YL, et al. A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood. 2000;96(2):452–458.
   PubMed Web of Science ®Google Scholar
• Giaccone L, Festuccia M, Marengo A, et al. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transpl: journal of the American Society for Blood and Marrow Transplantation. 2010 Jun;16(6):809–817. PubMed PMID: 20060484; eng.
   PubMed Web of Science ®Google Scholar
• Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology. 2002 Mar;122(3):614–624. PubMed PMID: 11874993; eng
   PubMed Web of Science ®Google Scholar
• Shouval D, Ilan Y. Transplantation of hepatitis B immune lymphocytes as means for adoptive transfer of immunity to hepatitis B virus. J Hepatol. 1995 Jul;23(1):98–101. PubMed PMID: 8530817; eng.
   PubMed Web of Science ®Google Scholar
• Park S, Kim K, Kim DH, et al. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol Blood Marrow Transpl: journal of the American Society for Blood and Marrow Transplantation. 2011 Nov;17(11):1630–1637. PubMed PMID: 21565276; eng.
   PubMed Web of Science ®Google Scholar
• Lindemann M, Barsegian V, Runde V, et al. Transfer of humoral and cellular hepatitis B immunity by allogeneic hematopoietic cell transplantation. Transplantation. 2003 Mar 27;75(6):833–838. PubMed PMID: 12660511; eng.
   PubMed Web of Science ®Google Scholar
• Marchou B, Excler JL, Bourderioux C, et al. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules. J Infect Dis. 1995 Jul;172(1):258–260. PubMed PMID: 7797926; eng
   PubMed Web of Science ®Google Scholar
• Knoll A, Boehm S, Hahn J, et al. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat. 2007 Jul;14(7):478–483. PubMed PMID: 17576389; eng.
   PubMed Web of Science ®Google Scholar
• Tavakolpour S, Alavian SM, Sali S. Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: a comprehensive review. Hepat Mon. 2016 Apr;16(4). PubMed PMID: 27257429.
   Web of Science ®Google Scholar
• Onozawa M, Hashino S, Darmanin S, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transpl: journal of the American Society for Blood and Marrow Transplantation. 2008 Nov;14(11):1226–1230. PubMed PMID: 18940676; eng. DOI:10.1016/j.bbmt.2008.08.007.
   PubMed Web of Science ®Google Scholar
• Takahata M, Hashino S, Onozawa M, et al. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Disease: an official journal of the Transplantation Society. 2014 Oct;16(5):797–801. PubMed PMID: 25154638; eng.
   PubMed Web of Science ®Google Scholar
• Mahale P, Thomas SK, Kyvernitakis A, et al., Management of multiple myeloma complicated by hepatitis c virus reactivation: The role of new antiviral therapy. Open Forum Infect Dis. 2016 Jan;3(1):ofv211. doi: 10.1093/ofid/ofv211
   PubMed Web of Science ®Google Scholar
• Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012 Dec;57(6):1177–1185. PubMed PMID: 22871500; eng.
   PubMed Web of Science ®Google Scholar
• Torres HA, Hosry J, Mahale P, et al. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology (Baltimore, MD). 2017;67(1):36–47.
   PubMedGoogle Scholar
• Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte programs. J Clin Oncol. 2006 Feb 20;24(6):953–960. PubMed PMID: 16418500; eng.
   PubMed Web of Science ®Google Scholar
• Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010 Dec 09;116(24):5119–5125. PubMed PMID: 20823454; eng.
   PubMed Web of Science ®Google Scholar
• Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. The Lancet. 1996;347(8994):92–93.
   PubMed Web of Science ®Google Scholar
• Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99(3):489–496. PubMed PMID: PMC3943312. DOI:10.3324/haematol.2013.094318.
   PubMed Web of Science ®Google Scholar
• McGovern BH, Birch CE, Bowen MJ, et al. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis. 2009;49(7):1051–1060.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England J Med. 2002;346(4):235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Österborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391.
   PubMed Web of Science ®Google Scholar
• Nishimori H, Matsuo K, Maeda Y, et al. The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. Int J Hematol. 2009;89(3):326–331.
   PubMed Web of Science ®Google Scholar
• IARC, Working, Group. HEPATITIS C VIRUS monograph. 2012 [cited 23 November 2017]. Available from: http://monographs.iarc.fr/ENG/Monographs/vol100B/mono100B-8.pdf.
   Google Scholar
• De Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6(4):451–458.
   PubMed Web of Science ®Google Scholar
• Libra M, Gasparotto D, Gloghini A, et al. Hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci: J Virtual Library. 2005 Sep 01;10:2460–2471. PubMed PMID: 15970508; eng.
   PubMedGoogle Scholar
• Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomark Prevent: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008 Nov;17(11):3069–3075. PubMed PMID: 18957521; PubMed Central PMCID: PMC2597453. eng.
   Google Scholar
• Libra M, Polesel J, Russo AE, et al. Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia? Int J Oncol. 2010 Jun;36(6):1331–1340. PubMed PMID: 20428756; eng
   PubMed Web of Science ®Google Scholar
• De Rosa G, Gobbo ML, De Renzo A, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol. 1997;55(2):77–82.
   PubMed Web of Science ®Google Scholar
• Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transpl: journal of the American Society for Blood and Marrow Transplantation. 2016 Apr;22(4):717–722. PubMed PMID: 26712592; PubMed Central PMCID: PMC4828726. eng.
   PubMed Web of Science ®Google Scholar
• EASL. Recommendations on treatment of hepatitis C. J Hepatol. 2017;66:153–194.
   Google Scholar
• Asselah T, Boyer N, Saadoun D, et al. Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectives. Liver Int. 2016;36(S1):47–57.
   PubMed Web of Science ®Google Scholar
• Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9(1):164.
   PubMedGoogle Scholar
• Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15(1):132–136.
   PubMed Web of Science ®Google Scholar
• Burgess S, Partovi N, Yoshida EM, et al. Drug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patients. Ann Pharmacother. 2015 Jun;49(6):674–687. PubMed PMID: 25770114; eng.
   PubMed Web of Science ®Google Scholar
• Peveling-Oberhag J, Arcaini L, Bankov K, et al. The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat. 2016 Jul;23(7):536–544. PubMed PMID: 26924533; eng.
   PubMed Web of Science ®Google Scholar
• Hermine O, Lefrère F, Bronowicki J-P, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. New England J Med. 2002;347(2):89–94.
   PubMed Web of Science ®Google Scholar
• Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004;18(10):1711–1716.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014;25(7):1404–1410.
   PubMed Web of Science ®Google Scholar
• La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol. 2008;49(4):557–563.
   PubMed Web of Science ®Google Scholar
• Rossotti R, Travi G, Pazzi A, et al. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol. 2015 Jan;62(1):234–237. PubMed PMID: 25285757; eng.
   PubMed Web of Science ®Google Scholar
• Sultanik P, Klotz C, Brault P, et al. Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood. 2015 Apr 9;125(15):2446–2447. DOI:10.1182/blood-2014-12-618652.
   PubMed Web of Science ®Google Scholar
• Carrier P, Jaccard A, Jacques J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Intl: official journal of the International Association for the Study of the Liver. 2015 Oct;35(10):2222–2227. PubMed PMID: 26104059; eng.
   PubMed Web of Science ®Google Scholar
• Alric L, Besson C, Lapidus N, et al. Antiviral treatment of HCV-infected patients with B-cell non-Hodgkin lymphoma: ANRS HC-13 lympho-C study. PloS One. 2016;11(10):e0162965. PubMed PMID: 27749916; PubMed Central PMCID: PMC5066969. Gilead, Roche, Schering-Plough/Merck, Abbott/ AbbVie,and grants from Bristol-Myers Squibb, Gilead, Roche and Merck. S. Pol has received consulting and lecturing fees from Bristol-Myers Squibb, Boehringer Ingelheim, Tibotec, Vertex, Gilead, Roche, Schering-Plough/Merck, Novartis, Abbott/ AbbVie,Sanofi and Glaxo Smith Kline, and grants from Bristol-Myers Squibb, Gilead, Roche and Merck/Schering Plough. P. Cacoub has received consulting and lecturing fees from Bristol-Myers Squibb, Gilead, Roche, MSD, Servier, and Vifor. D. Bonnet, C. Besson, N. Lapidus, J. Jeannel, J.M. Michot, D. Canioni, F. Davi, P. Rabiega, L. Ysebaert and O. Hermine declare that they do not have anything to disclose regarding conflict of interest with respect to this manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials. eng. DOI:10.1371/journal.pone.0162965.
   PubMed Web of Science ®Google Scholar
• Galati G, Rampa L, Vespasiani-Gentilucci U, et al. Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy. World J Hepatol. 2016 Oct 18;8(29):1244–1250. PubMed PMID: 27803769; PubMed Central PMCID: PMC5067444. eng.
   PubMedGoogle Scholar
• Lim LY, La D, Cserti-Gazdewich CM, et al. Lymphoma remission by interferon-free HCV eradication without chemotherapy. ACG Case Rep J. 2015;3(1):69.
   PubMed Web of Science ®Google Scholar
• Economides M, Mahale P, Kyvernitakis A, et al. Concomitant use of direct‐acting antivirals and chemotherapy in hepatitis C virus‐infected patients with cancer. Aliment Pharmacol Ther. 2016;44(11–12):1235–1241.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Besson C, Frigeni M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527–2532.
   PubMed Web of Science ®Google Scholar
• Hattori N, Ikeda H, Nakano H, etal. Curative effects for b-cell lymphoma accomplished by direct-acting antiviral agents of hepatitis C. Open Forum Infect Dis. 2017 Mar 25;4(2):ofx057. doi: 10.1093/ofid/ofx057.
   PubMed Web of Science ®Google Scholar
• Persico M, Aglitti A, Caruso R, et al. Efficacy and safety of new direct antiviral agents in HCV infected patients with diffuse large B cell non‐hodgkin lymphoma. Hepatology (Baltimore, MD). 2017;67(1):48–55.
   Google Scholar
• Tsutsumi Y, Nakayama C, Kamada K, et al. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann Hematol. 2017;96(12):2057–2061 .
   PubMed Web of Science ®Google Scholar
• Nakasone H, Kurosawa S, Yakushijin K, et al. Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. Am J Hematol. 2013 Jun;88(6):477–484. PubMed PMID: 23483626; eng.
   PubMed Web of Science ®Google Scholar
• Chen C-T, Liu C-Y, Yu Y-B, et al. Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. PloS One. 2017;12(9):e0185210.
   PubMed Web of Science ®Google Scholar
• Barba P, Piñana JL, Fernández-Avilés F, et al. Pretransplantation liver function impacts on the outcome of allogeneic hematopoietic stem cell transplantation: a study of 455 patients. Biol Blood Marrow Transplant. 2011;17(11):1653–1661.
   PubMed Web of Science ®Google Scholar
• De Latour RP, Ribaud P, Robin M, et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol. 2008;48(6):1008–1017.
   PubMed Web of Science ®Google Scholar
• Piñana J, Serra M, Hernández‐Boluda J, et al. Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant. Transpl Infect Dis. 2016;18(1):89–92.
   PubMed Web of Science ®Google Scholar
• Zaaijer HL, Kok M, Lelie PN, et al. Hepatitis E in the Netherlands: imported and endemic. Lancet. 1993;341(8848):826. DOI:10.1016/0140-6736(93)90599-C.
   PubMed Web of Science ®Google Scholar
• Mansuy J-M, Bendall R, Legrand-Abravanel F, et al. Hepatitis E virus antibodies in blood donors, France. 2011;17:2309–2312.
   Google Scholar
• Said B, Ijaz S, Kafatos G, et al. Hepatitis E outbreak on cruise ship. Emerg Infect Dis. 2009;15(11):1738–1744.
   PubMed Web of Science ®Google Scholar
• Legrand-Abravanel F, Kamar N, Sandres-Saune K, et al. Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis. 2010;202(6):835–844.
   PubMed Web of Science ®Google Scholar
• Sauleda S, Ong E, Bes M, et al. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription‐mediated amplification assay in blood donors from Catalonia (Spain). Transfusion. 2015;55(5):972–979.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Yoshida T, Kimata N, et al. Prevalence of hepatitis E virus infection in regular hemodialysis patients. Ther Apher Dial. 2006;10(2):193–197.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Pischke S, Manns MP. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology. 2012;142(6):1388–1397. e1.
   PubMed Web of Science ®Google Scholar
• Woolson K, Forbes A, Vine L, et al. Extra‐hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther. 2014;40(11–12):1282–1291.
   PubMed Web of Science ®Google Scholar
• Tavitian S, Péron J-M, Huynh A, et al. Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. J Clin Virol. 2010;49(2):141–144.
   PubMed Web of Science ®Google Scholar
• McPherson S, Elsharkawy AM, Ankcorn M, et al. Summary of the British Transplantation Society UK Guidelines for hepatitis E and solid organ transplantation. Transplantation. 2017.;102(1):15–20
   Web of Science ®Google Scholar
• Dalton HR, Hunter JG, Bendall RP. Hepatitis e. Curr Opin Infect Dis. 2013;26(5):471–478.
   PubMed Web of Science ®Google Scholar
• Singh A, Seth R, Gupta A, et al. Chronic hepatitis E–an emerging disease in an immunocompromised host. Gastroenterol Rep. 2016;gow024.
   Google Scholar
• Le Coutre P, Meisel H, Hofmann J, et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut. 2009;58(5):699–702.
   PubMed Web of Science ®Google Scholar
• Geng Y, Zhang H, Huang W, et al. Persistent hepatitis e virus genotype 4 infection in a child with acute lymphoblastic leukemia. Hepat Mon. 2014;14:1.
   Web of Science ®Google Scholar
• Clayson ET, Myint KSA, Snitbhan R, et al. Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Diseas. 1995;172(4):927–933.
   PubMed Web of Science ®Google Scholar
• Schnegg A, Bürgisser P, André C, et al. An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population. PloS One. 2013;8(5):e62980.
   PubMed Web of Science ®Google Scholar
• Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology. 2011;140(5):1481–1489.
   PubMed Web of Science ®Google Scholar
• Kamar N, Abravanel F, Selves J, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation. 2010;89(3):353–360.
   PubMed Web of Science ®Google Scholar
• van der Eijk AA, Pas SD, Cornelissen JJ, et al. Hepatitis E virus infection in hematopoietic stem cell transplant recipients. Curr Opin Infect Dis. 2014;27(4):309–315.
   PubMed Web of Science ®Google Scholar
• Riezebos-Brilman A, Verschuuren EA, van Son WJ, et al. The clinical course of hepatitis E virus infection in patients of a tertiary Dutch hospital over a 5-year period. J Clin Virol. 2013;58(3):509–514.
   PubMed Web of Science ®Google Scholar
• Debing Y, Emerson SU, Wang Y, et al. Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is moderately synergistic with alpha interferon. Antimicrob Agents Chemother. 2014;58(1):267–273. PubMed PMID: 24145541; PubMed Central PMCID: PMC3910773. eng. DOI:10.1128/aac.01795-13.
   PubMed Web of Science ®Google Scholar
• Kamar N, Izopet J, Tripon S, et al. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med. 2014 Mar 20;370(12):1111–1120. PubMed PMID: 24645943; eng.
   PubMed Web of Science ®Google Scholar
• Abravanel F, Lhomme S, Rostaing L, et al. Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. Clin Infect Dis. 2015;60(1):96–99.
   PubMed Web of Science ®Google Scholar
• Donnelly MC, Imlach SN, Abravanel F, et al. Sofosbuvir and daclatasvir anti–viral therapy fails to clear HEV viremia and restore reactive T cells in a HEV/HCV co-infected liver transplant recipient. Gastroenterology. 2017;152(1):300–301.
   PubMed Web of Science ®Google Scholar
• van der Valk M, Zaaijer HL, Kater AP, et al. Sofosbuvir shows antiviral activity in a patient with chronic hepatitis E virus infection. J Hepatol. 2017;66(1):242–243.
   PubMedGoogle Scholar
• Todesco E, Demeret S, Calin R, et al. Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of sofosbuvir–ribavirin. AIDS. 2017;31(9):1346–1348.
   PubMed Web of Science ®Google Scholar